{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:27:55Z","timestamp":1790731675604,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015050","name":"Sociedad Espa\u00f1ola de Epilepsia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024207","name":"Angelini Pharma Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nrleng.2026.502033","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:45:25Z","timestamp":1779839125000},"page":"502033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cenobamate: a new drug that may change the concept of drug-resistant focal epilepsy"],"prefix":"10.1016","volume":"41","author":[{"given":"J.J.","family":"Poza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2026.502033_bib0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.nrl.2011.04.002","article-title":"FEEN: Informe sociosanitario FEEN sobre la epilepsia en Espa\u00f1a","volume":"26","author":"Garc\u00eda-Ramos","year":"2011","journal-title":"Neurologia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0010","series-title":"Ambrosetti on Global Burden of Disease data","year":"2022"},{"key":"10.1016\/j.nrleng.2026.502033_bib0015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/epi.13723","article-title":"The impact of seizures on epilepsy outcomes: a national, community-based survey","volume":"58","author":"Josephson","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment Outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2026.502033_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109179","article-title":"The impact of epilepsy on quality of life: findings from a European survey","volume":"142","author":"Strzelczyk","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/epd2.20292","article-title":"Determinants of health-related quality of life of patients with focal epilepsy: a systematic literature review","volume":"27","author":"Engelhart","year":"2024","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.nrleng.2026.502033_bib0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nrleng.2026.502033_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nrleng.2026.502033_bib0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2026.502033_bib0050","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0055","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/epi.17564","article-title":"Failure to use new breakthrough treatments for epilepsy","volume":"64","author":"Klein","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0060","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0065","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.502033_bib0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.107014","article-title":"Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency","volume":"186","author":"Aboumatar","year":"2022","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.nrleng.2026.502033_bib0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.seizure.2024.04.017","article-title":"Efficacy and safety of adjunctive cenobamate based on patient etiology: post-hoc analysis of YKP3089C017 randomized clinical trial","volume":"118","author":"Xu","year":"2024","journal-title":"Seizure"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0085","first-page":"1","article-title":"Efficacy of adjunctive cenobamate for patients with different epilepsy aetiologies: results of an open-label study","volume":"65","author":"Serratosa","year":"2025","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0090","first-page":"1","article-title":"Long-term patient retention rates with cenobamate in patients with different epilepsy aetiologies","volume":"65","author":"Toledo","year":"2025","journal-title":"Epilepsia"},{"issue":"Pt A","key":"10.1016\/j.nrleng.2026.502033_bib0095","article-title":"Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice","volume":"104","author":"Verrotti","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","article-title":"Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications","volume":"96","author":"Brandt","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.nrleng.2026.502033_bib0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.nrleng.2026.502033_bib0110","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/epi4.12997","article-title":"Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis","volume":"9","author":"Zhang","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.nrleng.2026.502033_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102513","article-title":"Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials","volume":"70","author":"Chen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.nrleng.2026.502033_bib0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","article-title":"A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis","volume":"118","author":"Mulheron","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.nrleng.2026.502033_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.109054","article-title":"Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain","volume":"139","author":"Villanueva","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0130","series-title":"XCOPRI\u00ae (cenobamate tablets), for oral use, CV [prescribing information]","year":"2020"},{"key":"10.1016\/j.nrleng.2026.502033_bib0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17134","article-title":"Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program","volume":"63","author":"Sander","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","article-title":"Real-world experience with cenobamate: a systematic review and meta-analysis","volume":"112","author":"Makridis","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.nrleng.2026.502033_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107796","article-title":"Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment","volume":"116","author":"Elizebath","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40263-025-01158-8","article-title":"Post-marketing experience with cenobamate in the treatment of focal epilepsies: a multicentre cohort study","volume":"39","author":"Strzelczyk","year":"2025","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0155","first-page":"1","article-title":"Real-world observational study of efficacy and tolerability of cenobamate in refractory focal epilepsy in a tertiary epilepsy surgery centre","volume":"65","author":"Boehm","year":"2025","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0160","first-page":"1","article-title":"An observational cross-sectional study to assess the impact of cenobamate","volume":"65","author":"Khazin","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0165","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/epi.17662","article-title":"Sudden unexpected death in epilepsy during cenobamate clinical development","volume":"64","author":"Rosenfeld","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2024.12.010","article-title":"Impact of lifetime antiepileptic drug history on cenobamate efficacy in adults with focal epilepsy","volume":"125","author":"Martinez-Lizana","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.nrleng.2026.502033_bib0175","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1111\/epi.18357","article-title":"Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: Interim results after 24-week observational period from the BLESS study","volume":"66","author":"Lattanzi","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107498","article-title":"Effectiveness and tolerability of cenobamate: a single center experience","volume":"209","author":"Saouda","year":"2025","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.nrleng.2026.502033_bib0185","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18297","article-title":"Real-world use of cenobamate in adults: efficacy and predictors of treatment response","volume":"66","author":"Loushy","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40263-024-01109-9","article-title":"Cenobamate as an early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study","volume":"38","author":"Winter","year":"2024","journal-title":"CNS Drugs"},{"issue":"Supl 1","key":"10.1016\/j.nrleng.2026.502033_bib0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2667-0496(24)00271-0","article-title":"Tendencias actuales en el inicio y eficacia cl\u00ednica de cenobamato: experiencia cl\u00ednica","volume":"4","author":"Boy Garc\u00eda","year":"2024","journal-title":"Neurol Perspect"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0200","first-page":"1","article-title":"Efficacy and safety of adjunctive cenobamate in elderly patients with uncontrolled focal seizures: experience in a single centre","volume":"65","author":"Gonz\u00e1lez Villar","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0205","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200151","article-title":"Cenobamate and Clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies","volume":"10","author":"Serrano-Castro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0210","first-page":"1","article-title":"Cenobamate effect in patients with autoimmune epilepsy","volume":"65","author":"Olivera","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S2667-0496(24)00278-3","article-title":"Cenobamato tras cirug\u00eda de la epilepsia. An\u00e1lisis retrospectivo de su uso en un centro de referencia","volume":"4","author":"Paz Tamayo","year":"2024","journal-title":"Neurol Perspect"},{"key":"10.1016\/j.nrleng.2026.502033_bib0220","series-title":"Poster SEEP","article-title":"Rocamora Zu\u00f1iga R Optimizaci\u00f3n del tratamiento con cenobambato en pacientes con epilepsia focal tras cirug\u00eda fallida","author":"\u00c1lvarez G\u00f3mez","year":"2024"},{"key":"10.1016\/j.nrleng.2026.502033_bib0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2667-0496(24)00884-6","article-title":"Experiencia con cenobamato (CNB) en una serie de pacientes con epilepsia focal farmacorresistente","volume":"4","author":"Castro Montenegro","year":"2024","journal-title":"Neurol Perspect"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0230","first-page":"1","article-title":"New frontiers in drug-resistant epilepsy: possible synergy between Vagus Nerve stimulation and cenobamate","volume":"65","author":"Vergobbi","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2022.01.001","article-title":"Initial real-world experience with cenobamate in adolescents and adults: a single center experience","volume":"129","author":"Elliott","year":"2022","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nrleng.2026.502033_bib0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","article-title":"Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study","volume":"111","author":"Beltr\u00e1n-Corbellini","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.nrleng.2026.502033_bib0245","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241256733","article-title":"Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations","volume":"17","author":"Steinhoff","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nrleng.2026.502033_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109605","article-title":"Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies","volume":"151","author":"Krauss","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","article-title":"Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study","volume":"38","author":"Serrano-Castro","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nrleng.2026.502033_bib0260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/epi4.12857","article-title":"Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy","volume":"9","author":"Catal\u00e1n-Aguilar","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.nrleng.2026.502033_bib0265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","article-title":"Effects of cenobamate on cognitive performance of epilepsy patients","volume":"102","author":"Schuetz","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.nrleng.2026.502033_bib0270","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1239152","article-title":"Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence?","volume":"14","author":"Pietrafusa","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nrleng.2026.502033_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107261","article-title":"Polypharmacy in patients with epilepsy: a nationally representative cross-sectional study","volume":"111","author":"Terman","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0280","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.nrleng.2026.502033_bib0285","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/epi4.12936","article-title":"Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures","volume":"9","author":"Carre\u00f1o","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.nrleng.2026.502033_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109156","article-title":"The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction","volume":"142","author":"Osborn","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.nrleng.2026.502033_bib0295","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/epi4.12959","article-title":"Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain","volume":"9","author":"Rodr\u00edguez-Uranga","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.nrleng.2026.502033_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107242","article-title":"Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review","volume":"197","author":"Becker","year":"2023","journal-title":"Epilepsy Res"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0305","first-page":"1","article-title":"Cenobamate: is it the drug which will transform the drug-resistant epilepsy paradigm?","volume":"65","author":"S\u00e1nchez-Guijo Benavente","year":"2025","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.502033_bib0310","first-page":"1","article-title":"Cenobamate as monotherapy or biotherapy with low doses of clobazam","volume":"65","author":"Gonz\u00e1lez Villar","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.nrleng.2026.502033_bib0315","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S2667-0496(24)00286-2","article-title":"Experiencia en pr\u00e1ctica cl\u00ednica real y rol de la enfermera especialista en epilepsia en el uso del cenobamato","volume":"4","author":"Ros Gonz\u00e1lez","year":"2024","journal-title":"Neurol Perspect"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:21:08Z","timestamp":1788866468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2173580826000933"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502033","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cenobamate: a new drug that may change the concept of drug-resistant focal epilepsy","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2026.502033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502033"}}